ARK 每周股评 – 8/7/2021


We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week. We hope you find this commentary useful.

Arcturus (ARCT)
+68%Arcturus (ARCT), a self-amplifying mRNA therapeutics and vaccines company, traded up 68% on Tuesday after announcing that Sanofi (SNY) would be acquiring Translate Bio (TBIO), an mRNA therapeutics company focused on rare diseases. The news that Arcturus struck a deal to manufacture vaccines for new SARS-CoV-2 variants in Singapore and Vietnam also apparently contributed to the upside. After a correction of 23% on Wednesday, Arcturus continued to trade up 20% on Thursday, likely in sympathy with the gene-editing and other genomics stocks.

注: 在宣布赛诺菲(SNY)将收购专注于罕见疾病的mRNA治疗公司Translate Bio(TBIO)之后,自扩mRNA治疗和疫苗公司Arcturus(ARCT)周二交易价格上涨68%。Arcturus达成了在新加坡和越南生产SARS-CoV-2新变种疫苗的协议,这一消息显然也促进了上涨。在周三回调23%之后,Arcturus周四继续上涨20%,可能是与基因编辑和其他基因组学股票相呼应。
Editas Medicine (EDIT)
+18%Editas Medicine (EDIT), a CRISPR-focused company leveraging gene editing to solve rare genetic diseases, traded up 18% on Tuesday, participating in the broad-based rally in gene-editing stocks. As noted above, Moderna’s CEO Stéphane Bancel also announced that he is interested in acquisitions that will add gene-editing technology to Moderna’s platform.

注: 艾迪塔斯医药公司(EDIT)是一家专注于CRISPR的公司,利用基因编辑来解决罕见的遗传疾病,周二交易价格上涨18%,参与了基因编辑股票的广泛反弹。如上所述,Moderna的首席执行官Stéphane Bancel还宣布,他对将基因编辑技术加入Moderna平台的收购感兴趣。
Cerus (CERS)
+21%Cerus (CERS), a leading provider of blood-based pathogen inactivation technology and advanced blood products, appreciated 21% on Wednesday after strong quarterly results that delivered record product revenue and higher than expected guidance. In our view, Cerus' newest therapeutic blood product, pathogen-reduced fibrinogen, is poised to drive topline growth for the foreseeable future. Recently, the Centers for Medicare and Medicaid Services (CMS) announced a premium reimbursement policy for fibrinogen that should galvanize its adoption in the United States.

注: 血液病原体灭活技术和先进血液产品的领先供应商Cerus (CERS)周三升值21%,此前该公司的季度业绩强劲,产品收入创下历史新高,并高于预期的指引。我们认为,Cerus最新的治疗性血液产品--病原体减少的纤维蛋白原,将在可预见的未来推动收入的增长。最近,美国医疗保险和医疗补助服务中心(CMS)宣布了纤维蛋白原的溢价报销政策,这应该会促进其在美国的应用。
Robinhood Markets (HOOD)
+50%Robinhood Markets (HOOD), a fintech company focused on commission-free investing products, trust, and transparency, experienced significant volatility after an initially lackluster response to its IPO last week, appreciating roughly 50% on Wednesday. Later in the week, a regulatory filing suggested that existing shareholders were free to sell up to 97.9 million shares but the company clarified on Friday that such sales will not take place for a few weeks as they will require SEC approval.

注: Robinhood Markets(HOOD)是一家专注于免佣金投资产品、信任和透明度的金融科技公司,在上周IPO最初反响平平后经历了大幅波动,周三升值了约50%。本周晚些时候,一份监管文件表明,现有股东可以自由出售多达9790万股股票,但该公司周五澄清,这种销售在几周内不会发生,因为它们需要美国证券交易委员会的批准。
Beam Therapeutics (BEAM)
+15%Beam Therapeutics (BEAM), a leader in base-editing genetic medicine, appreciated 15% on Thursday, participating in a broad-based rally in gene-editing stocks. Also contributing to the rally was Moderna's (MRNA) earnings call during which CEO Stéphane Bancel announced that he is interested in acquisitions that will add gene-editing technology to Moderna’s platform.

注: Beam Therapeutics (BEAM)是基数编辑基因医学的领导者,周四升值15%,参与了基因编辑股票的广泛涨势。Moderna (MRNA)的财报电话会议也促进了这一反弹,首席执行官Stéphane Bancel在电话会议上宣布,他对将基因编辑技术加入Moderna平台的收购感兴趣。
Caribou Biosciences (CRBU)
+20%Caribou Biosciences (CRBU), a CRISPR-focused therapeutics company that went public recently, traded up 20% on Thursday for reasons described above under Beam and Editas.

注: Caribou Biosciences(CRBU)是一家最近上市的以CRISPR为重点的治疗公司,周四交易价格上涨20%,原因见上文Beam和Editas一节。
Dicerna Pharmaceuticals (DRNA)
-36%Dicerna Pharmaceuticals (DRNA), which develops RNA interference and gene silencing therapeutics, dropped 36% on Thursday after announcing that its drug candidate for rare disease hyperoxaluria Nedosiran, met its primary endpoints but delivered inconsistent results for some subtypes of the disease.

注: 开发RNA干扰和基因沉默疗法的Dicerna制药公司(DRNA)周四下跌了36%,此前该公司宣布其治疗罕见疾病高氧尿症的候选药物Nedosiran达到了主要终点,但对该疾病的某些亚型产生了不一致的结果。
Sarepta Therapeutics (SRPT)
+16%Sarepta Therapeutics (SRPT), a medical research company developing engineering solutions for rare diseases, traded up 16% Thursday after topping revenue expectations and executing a license agreement for a gene therapy candidate targeting limb-girdle muscular dystrophy.

注: Sarepta Therapeutics (SRPT)是一家为罕见疾病开发工程解决方案的医学研究公司,周四上涨16%,此前该公司的收入高于预期,并执行了一项针对肢体腰部肌肉萎缩症的候选基因疗法许可协议。
Zymergen (ZY)
+75%Zymergen (ZY), a newly public synthetic biology company, closed down 76% on Wednesday and then reversed and rose 75% the following day. Sized at fewer than 40 basis points in our genomics strategy before the drama, Zymergen announced that several of its early-access customers had faced challenges integrating its lead biofilm asset, Hyaline, into their manufacturing processes and that, worse still, the addressable market for Hyaline could be lower than management had expected and could take longer to evolve. In response to this setback, Zymergen’s Board announced that Director Jay Flatley, who had an impactful career at Illumina, had agreed to step into the role of Acting CEO until a turnaround is under way.
While our confidence has been reduced in its short-term outlook, we  believe that Zymergen’s platform holds deep intrinsic value and that the total addressable market for products produced with synthetic biology is vast, enough so for multiple approaches and models to flourish simultaneously.

注: Zymergen(ZY)是一家新上市的合成生物学公司,周三收盘下跌76%,然后在第二天反转并上涨75%。在我们的基因组学战略中,Zymergen公司在大戏上演前的估值不到40个基点,它宣布其几个早期客户在将其主要的生物膜资产Hyaline整合到他们的生产过程中面临挑战,更糟糕的是,Hyaline的可寻址市场可能低于管理层的预期,可能需要更长的时间来发展。为了应对这一挫折,Zymergen的董事会宣布,曾在Illumina公司有影响力的董事Jay Flatley同意担任代理首席执行官,直到出现转机。


上一篇 2021年8月9日 下午12:28
下一篇 2021年8月10日 上午10:37